Richard L. Cullum
Affiliations: | 2020 | Chemical Engineering | Auburn University, Auburn, AL, United States |
Google:
"Richard Cullum"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Lucas LM, Dwivedi V, Senfeld JI, et al. (2022) The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein. Pharmacological Reviews. 74: 18-47 |
| Cullum RL, Lucas LM, Senfeld JI, et al. (2020) Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics. Plos One. 15: e0243901 |
| Cullum RL, Ghosh T, Lucas L, et al. (2019) Abstract 2144: Mutations in ERBB4 may account for clinical resistance of melanomas to inhibitors of the RAS/RAF/MEK/MAPK pathway Cancer Research. 79: 2144-2144 |
| Cullum RL, Lucas LM, Piazza JT, et al. (2018) Abstract A159: Characterization of putative ErbB4 antagonists: targeted melanoma drug discovery Molecular Cancer Therapeutics. 17 |
| Cullum RL, Piazza JT, Senfeld JI, et al. (2017) Abstract 1245: Screening methodologies for the discovery of small molecule melanoma therapeutics targeted at the ErbB4 receptor tyrosine kinase Cancer Research. 77: 1245-1245 |
| Cullum R, David A, Riese DJ. (2016) Abstract 1353: Validation and implementation of screens for partial agonists and antagonists of the ErbB4/HER4 receptor tyrosine kinase: Targeted melanona drug discovery Cancer Research. 76: 1353-1353 |
| Cullum RL, Gupta RB, Riese DJ. (2015) Abstract B17: A high-throughput screening process for the discovery of melanoma chemotherapeutics targeted at the ErbB4 receptor tyrosine kinase Cancer Research. 75 |
| Riese DJ, Cullum RL. (2014) Epiregulin: roles in normal physiology and cancer. Seminars in Cell & Developmental Biology. 28: 49-56 |